Company

Hummingbird Bioscience

A Singapore-headquartered antibody drug developer. It designs monoclonal antibodies and antibody-drug conjugates against targets it selects computationally, then develops them for cancer and autoimmune disease. Current clinical assets are HMBD-001 (anti-HER3 antibody) and HMBD-501 (a HER3-directed antibody-drug conjugate, dosed in its first Phase I patient in January 2026). It has also out-licensed programmes: HMBD-002 (anti-VISTA) to Percheron Therapeutics in June 2025, and an undisclosed-target antibody to Immunome in January 2025. Its longevity relevance is indirect rather than direct. It does not work on ageing biology, senescence, metabolic ageing or healthspan endpoints. The connection is that cancer is a leading age-related cause of death, so better-targeted oncology therapeutics extend life in an older population. Read as an oncology biotech that sits in the SG/AU universe on headquarters grounds, not as a geroscience company.

At a glance

Listing: Private, not listed
Category: Pharma
Headquarters: The Galen, 61 Science Park Road, #06-15, Singapore 117525
Market cap: Not disclosed

Thesis

Why it is in this universe

Category: Pharma
Market: Singapore
Recent inflection: 6 January 2026: first patient dosed in the Phase I clinical trial of HMBD-501 in patients with advanced HER3-expressing solid malignancies (company news page, hummingbirdbioscience.com/news).
Services: None recorded
People tracked: None on file

Market data

Listing and scale

Metric	Detail
Exchange	Unlisted
Ticker	None
Secondary listing	None
Market cap	Not disclosed
Status	Private

Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.

Get in touch

Contact

Address: The Galen, 61 Science Park Road, #06-15, Singapore 117525
Website: hummingbirdbioscience.com
Phone: No public number published
Email: No public address published

Offering

What it sells today

No commercial services are recorded for this company yet.

Recent inflection

What moved lately

6 January 2026: first patient dosed in the Phase I clinical trial of HMBD-501 in patients with advanced HER3-expressing solid malignancies (company news page, hummingbirdbioscience.com/news).

Common questions

Why does variis track Hummingbird Bioscience?: A Singapore-headquartered antibody drug developer. It designs monoclonal antibodies and antibody-drug conjugates against targets it selects computationally, then develops them for cancer and autoimmune disease. Current clinical assets are HMBD-001 (anti-HER3 antibody) and HMBD-501 (a HER3-directed antibody-drug conjugate, dosed in its first Phase I patient in January 2026). It has also out-licensed programmes: HMBD-002 (anti-VISTA) to Percheron Therapeutics in June 2025, and an undisclosed-target antibody to Immunome in January 2025. Its longevity relevance is indirect rather than direct. It does not work on ageing biology, senescence, metabolic ageing or healthspan endpoints. The connection is that cancer is a leading age-related cause of death, so better-targeted oncology therapeutics extend life in an older population. Read as an oncology biotech that sits in the SG/AU universe on headquarters grounds, not as a geroscience company.
Is Hummingbird Bioscience publicly listed?: variis has no ticker on file for Hummingbird Bioscience, so it is tracked as private or unlisted. Absence of a ticker on this record is not a statement that no listing exists anywhere.
Where is Hummingbird Bioscience based?: The Galen, 61 Science Park Road, #06-15, Singapore 117525
Is Hummingbird Bioscience still trading?: Hummingbird Bioscience is recorded as private.

Keep reading

Related coverage from the newsroom.

Singapore and Australia · Capital

Two rounds, one IPO: how Singapore and Australia are funding longevity in 2025 to 2026

Suggest an update

Sources

What this profile is built on

Hummingbird Bioscience: engineering precision biotherapeutics (homepage, HQ address and pipeline) · Hummingbird Bioscience
Hummingbird Bioscience news archive (2025-2026 announcements) · Hummingbird Bioscience

Last updated 14 August 2026

Every entity profile on variis is sourced. Not investment advice.

Metric

Detail

Exchange

Unlisted

Ticker

None

Secondary listing

None

Market cap

Not disclosed

Status

Private

Common questions

Why does variis track Hummingbird Bioscience?

A Singapore-headquartered antibody drug developer. It designs monoclonal antibodies and antibody-drug conjugates against targets it selects computationally, then develops them for cancer and autoimmune disease. Current clinical assets are HMBD-001 (anti-HER3 antibody) and HMBD-501 (a HER3-directed antibody-drug conjugate, dosed in its first Phase I patient in January 2026). It has also out-licensed programmes: HMBD-002 (anti-VISTA) to Percheron Therapeutics in June 2025, and an undisclosed-target antibody to Immunome in January 2025. Its longevity relevance is indirect rather than direct. It does not work on ageing biology, senescence, metabolic ageing or healthspan endpoints. The connection is that cancer is a leading age-related cause of death, so better-targeted oncology therapeutics extend life in an older population. Read as an oncology biotech that sits in the SG/AU universe on headquarters grounds, not as a geroscience company.

Is Hummingbird Bioscience publicly listed?

variis has no ticker on file for Hummingbird Bioscience, so it is tracked as private or unlisted. Absence of a ticker on this record is not a statement that no listing exists anywhere.

Where is Hummingbird Bioscience based?

The Galen, 61 Science Park Road, #06-15, Singapore 117525

Is Hummingbird Bioscience still trading?

Hummingbird Bioscience is recorded as private.